P1231: ZILOVERTAMAB VEDOTIN (MK-2140) FOR THE TREATMENT OF NON-HODGKIN LYMPHOMA: THE PHASE 1 DOSE ESCALATION AND COHORT EXPANSION WAVELINE-001 STUDY OF AN ANTI-ROR1 ANTIBODY-DRUG C... by M. Wang, M. Mei, P. M. Barr, J. Barrientos, S. de Vos, R. Furman, K. Patel, P. A. Thompson, M. Choi, A. Kallam, Y. Zhu, S. Chakraborty, P. Marinello, S. E. Spurgeon

Get full text

PB1878: CROSS-TRIAL ANALYSIS OF FIXED-DURATION IBRUTINIB (I) PLUS VENETOCLAX (V) VS FLUDARABINE (F), CYCLOPHOSPHAMIDE (C), AND RITUXIMAB (R) AS FIRST-LINE TREATMENT FOR CHRONIC LYM... by J. C. Barrientos, P. M. Barr, A. R. Mato, C. S. Tam, P. Ghia, C. Moreno, N. E. Kay, T. Siddiqi, E. Szafer-Glusman, C. Zhou, L. Neumayr, G. Krigsfeld, W. G. Wierda, T. Shanafelt

Get full text

P669: FIXED-DURATION (FD) IBRUTINIB + VENETOCLAX FOR FIRST-LINE TREATMENT OF CHRONIC LYMPHOCYTIC LEUKEMIA (CLL)/SMALL LYMPHOCYTIC LYMPHOMA (SLL): 3-YEAR FOLLOW-UP FROM THE PHASE 2... by C. Moreno, W. G. Wierda, P. M. Barr, T. Siddiqi, J. N. Allan, T. J. Kipps, L. Trentin, R. Jacobs, S. Jackson, A. Tedeschi, S. Opat, R. Bannerji, B. J. Kuss, L. J. Croner, E. Szafer-Glusman, C. Zhou, A. Szoke, J. P. Dean, P. Ghia, C. S. Tam

Get full text

P671: TREATMENT SEQUENCES AND OUTCOMES OF PATIENTS WITH CLL TREATED WITH TARGETED AGENTS IN REAL-WORLD SETTINGS by A. R. Mato, B. S. Manzoor, C. C. Coombs, N. Lamanna, H. H. Tuncer, J. R. Brown, L. E. Roeker, M. Shadman, J. N. Allan, C. Ujjani, B. Eichhorst, L. Leslie, I. Fleury, H. Alhasani, J. Rhodes, B. T. Hill, P. M. Barr, A. Skarbnik, M. S. Davids, R. Bannerji, M. Fuldeore, F. Lansigan, A. Schuh, L. Pearson, C. P. Fox, I. Pivneva, L. Popadic, A. Guerin, T. A. Eyre

Get full text